|
Name |
Aspernolide A
|
Molecular Formula | C24H24O7 | |
IUPAC Name* |
methyl (2R)-2-[(2,2-dimethyl-3,4-dihydrochromen-6-yl)methyl]-4-hydroxy-3-(4-hydroxyphenyl)-5-oxofuran-2-carboxylate
|
|
SMILES |
CC1(CCC2=C(O1)C=CC(=C2)C[C@@]3(C(=C(C(=O)O3)O)C4=CC=C(C=C4)O)C(=O)OC)C
|
|
InChI |
InChI=1S/C24H24O7/c1-23(2)11-10-16-12-14(4-9-18(16)30-23)13-24(22(28)29-3)19(20(26)21(27)31-24)15-5-7-17(25)8-6-15/h4-9,12,25-26H,10-11,13H2,1-3H3/t24-/m1/s1
|
|
InChIKey |
YCHNFUWRXHTAFK-XMMPIXPASA-N
|
|
Synonyms |
Aspernolide A; CHEMBL4068225; BDBM50453563; methyl (2R)-2-[(2,2-dimethyl-3,4-dihydrochromen-6-yl)methyl]-4-hydroxy-3-(4-hydroxyphenyl)-5-oxofuran-2-carboxylate; methyl (2R)-2-[(2,2-dimethylchroman-6-yl)methyl]-4-hydroxy-3-(4-hydroxyphenyl)-5-oxo-furan-2-carboxylate
|
|
CAS | NA | |
PubChem CID | 25265784 | |
ChEMBL ID | CHEMBL4068225 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 424.4 | ALogp: | 3.8 |
HBD: | 2 | HBA: | 7 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 102.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 31 | QED Weighted: | 0.709 |
Caco-2 Permeability: | -4.964 | MDCK Permeability: | 0.00002180 |
Pgp-inhibitor: | 0.962 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.513 |
30% Bioavailability (F30%): | 0.883 |
Blood-Brain-Barrier Penetration (BBB): | 0.037 | Plasma Protein Binding (PPB): | 98.36% |
Volume Distribution (VD): | 0.369 | Fu: | 1.15% |
CYP1A2-inhibitor: | 0.221 | CYP1A2-substrate: | 0.801 |
CYP2C19-inhibitor: | 0.908 | CYP2C19-substrate: | 0.415 |
CYP2C9-inhibitor: | 0.937 | CYP2C9-substrate: | 0.916 |
CYP2D6-inhibitor: | 0.57 | CYP2D6-substrate: | 0.73 |
CYP3A4-inhibitor: | 0.94 | CYP3A4-substrate: | 0.629 |
Clearance (CL): | 10.662 | Half-life (T1/2): | 0.148 |
hERG Blockers: | 0.054 | Human Hepatotoxicity (H-HT): | 0.645 |
Drug-inuced Liver Injury (DILI): | 0.639 | AMES Toxicity: | 0.19 |
Rat Oral Acute Toxicity: | 0.51 | Maximum Recommended Daily Dose: | 0.623 |
Skin Sensitization: | 0.048 | Carcinogencity: | 0.534 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.012 |
Respiratory Toxicity: | 0.024 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002900 | 0.794 | D06TJJ | 0.306 | ||||
ENC003498 | 0.686 | D0Q9ON | 0.280 | ||||
ENC002376 | 0.680 | D01XBA | 0.276 | ||||
ENC003721 | 0.646 | D0JY8T | 0.270 | ||||
ENC002571 | 0.629 | D0J7RK | 0.265 | ||||
ENC000875 | 0.629 | D06XZW | 0.265 | ||||
ENC002729 | 0.629 | D04UTT | 0.262 | ||||
ENC002552 | 0.617 | D06HBQ | 0.260 | ||||
ENC002705 | 0.606 | D08CCE | 0.259 | ||||
ENC002711 | 0.606 | D0Y2NE | 0.257 |